Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06972719 · ClinicalTrials.gov registry record · NA
Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
A NA study of BRCA1 Mutation and BRCA2 Mutation, sponsored by Duke University.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06972719: Recruiting NA study of BRCA1 Mutation and BRCA2 Mutation, sponsored by Duke University.
NCT06972719 is a NA study of BRCA1 Mutation and BRCA2 Mutation that is actively recruiting participants, run by Duke University. The registered enrollment target is 50 participants, below the 574-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06972719, a NA study of BRCA1 Mutation and BRCA2 Mutation, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to develop an educational aid about hormone replacement therapy that physicians can share with patients as part of their pre-surgical counseling for a risk-reducing salpingo-oophorectomy (RRSO).
Primary Outcome
The Decisional Conflict Scale ranges from 16 to 80 with a higher score indicating greater conflict with the decision.
Conditions Studied
Interventions
- BEHAVIORAL Experimental Arm
- BEHAVIORAL SOC Arm
Study Locations (1)
North Carolina
- Duke University Health System - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT06972719 shows while recruiting
NCT06972719 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 574-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with BRCA1 Mutation appearing as the primary indexed condition, and to 2 interventions - of which Experimental Arm is the first listed.
NCT06972719 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06972719 about?
NCT06972719 is a clinical study titled "Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy". The goal of this study is to develop an educational aid about hormone replacement therapy that physicians can share with patients as part of their pre-surgical counseling for a risk-reducing salpingo-oophorectomy (RRSO).
What is the current status of trial NCT06972719?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-09-30. Estimated completion is 2026-12-31.
What conditions does trial NCT06972719 study?
This clinical trial studies the following conditions: BRCA1 Mutation, BRCA2 Mutation.
What interventions are being tested in trial NCT06972719?
The interventions under investigation include: Experimental Arm (BEHAVIORAL), SOC Arm (BEHAVIORAL).
Who is sponsoring clinical trial NCT06972719?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06972719 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BRCA1 Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06972719's enrollment target sits among peer trials
50 9th of 15 higher than 6 of 15 other BRCA1 Mutation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other BRCA1 Mutation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results
RECRUITING · NA
-
FaCT Trial (Facilitated Cascade Testing Trial)
RECRUITING · NA
-
Decision Support for BRCA Testing in Ethnically Diverse Women
COMPLETED · NA
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Combination Therapy in Cancers With Mutations in DNA Repair Genes
RECRUITING · Phase 1
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI